Mimedx (MDXG) EPS (Weighted Average and Diluted) (2012 - 2026)

Mimedx has disclosed EPS (Weighted Average and Diluted) across 15 years of filings, most recently posting -$0.07 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at -$0.07, down 240.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $0.2 (down 25.93% YoY), and the FY2025 annual result was $0.32, up 14.29% from the prior year.
• EPS (Weighted Average and Diluted) came in at -$0.07 for Q1 2026 at Mimedx, down from $0.1 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.37 in Q4 2023 to a low of -$0.11 in Q1 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.05 (2024), against an average of $0.04.
• Across the five-year window, EPS (Weighted Average and Diluted) tumbled 266.67% in 2022 and soared 1100.0% in 2024, its largest moves.
• Mimedx's EPS (Weighted Average and Diluted) stood at $0.07 in 2022, then surged by 428.57% to $0.37 in 2023, then sank by 86.49% to $0.05 in 2024, then soared by 100.0% to $0.1 in 2025, then slumped by 170.0% to -$0.07 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at -$0.07 (Q1 2026), $0.1 (Q4 2025), and $0.11 (Q3 2025), per Business Quant data.